Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib vs Sunitinib in Asian Advanced RCC
NCT01147822Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2010
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of pazopanib in renal cell carcinoma (RCC) (2 arms), sponsored by Novartis. Primary endpoint: Progression-free Survival at 24 months. Started May 2010; status: completed.
02
Drugs
pazopanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01147822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01147822.